Repeated Use of BRAF and MEK Inhibitors in Patients with BRAF-Mutated Metastatic Melanoma of the Skin

In this paper we review the existing data and our clinical experience of repeated use of combination therapy with BRAF/MEK inhibitors (BRAFi/MEKi) in the treatment of patients with BRAF-mutated metastatic melanoma of the skin. Recent advances in medical oncology significantly increased the life expectancy of patients with metastatic and/or unresectable melanoma of the skin. However, some patients develop resistance to therapy. Retreatment after interruption or "intermediate" therapy may be of clinical benefit. Contemporary drug therapy becomes more available and there are fewer challenges to chose the first and second line therapy for patients with metastatic and/or unresectable melanoma, but there are still questions on subsequent treatment options when BRAFi/MEKi therapy had been used after the disease progression following the initial objective response. In this article, we review the definitions of “retreatment” or “rechallenge”, give the overview of the literature data, and present our clinical experience